ClinicalTrials.gg
RecruitingNCT05736146Updated Jul 24, 2025

Validating Gulf War Illness Blood Biomarkers

An observational study in Gulf War Syndrome and Gulf War Illness, sponsored by Roskamp Institute Inc.. Recruiting at 3 sites in United States. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Roskamp Institute Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Persian Gulf Syndrome with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Persian Gulf Syndrome · United States.

Started
2022
the only one that year
Observational
9 of 41
1 open now
Registered
35th of 41
by date

Among the 41 studies in Persian Gulf Syndrome with a site in United States, this one is the only one that started in 2022, is one of 9 observational ones, and was the 35th registered.

Persian Gulf Syndrome

41 studies on the registry are indexed under Persian Gulf Syndrome; 9 are open to participants now.

Browse Persian Gulf Syndrome studies →

Open to participants now

9 of the 41 studies in Persian Gulf Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Persian Gulf Syndrome studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 35 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Persian Gulf Syndrome with a site in United States, or all of them as a file.
02

Study summary

The investigators goals are to identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI. To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.

Read the detailed description

Nearly 30 years later, veterans with Gulf War Illness (GWI) continue to suffer from this persistent and debilitating illness, which remains difficult to diagnose due to the heterogeneity of clinical presentation and the complexity of biological responses to hazardous chemicals to which GW veterans were exposed during the 1990-1991 Gulf War (GW). Brain imaging studies of veterans with GWI and pre-clinical animal studies of rodents with GWI show that impaired bioenergetics and inflammation can be attributed to the atrophy of the axonal white matter tracts that link the cortical gray matter regions, and the alterations of lipid/metabolite levels. The investigators recent work shows that disturbed lipid profiles in the brain and blood after GW pesticide exposure in rodents accompany neurobehavioral and bioenergetics deficits and inflammation. The mechanisms of neurotoxicity after pesticide exposure include increases in the inactivation of lipid metabolizing enzymes. This may consequently result in accumulation of lipids in the body compartments that limit their availability for use as energy substrates, contributing to bioenergetic impairments and inflammation. These metabolic changes have also been linked to individuals who possess the apolipoprotein E (APOE) ε4 allele, a risk factor of aging related cognitive decline and neurodegenerative conditions, such as Alzheimer's disease (AD). Several studies have shown a correlation between lipid transport deficits and presence of the ε4 allele. The identification of specific lipids/metabolites and the APOE ε4 allele as important biomarkers of GWI would serve to objectively assess the brain pathology of GWI and identify subgroups of GWI based on symptom patterns and GW exposures.

03

Conditions studied

  • Gulf War Syndrome
  • Gulf War Illness

Browse trials for

Keywords

  • Gulf War
  • APOE
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Veterans who served in the Gulf War during 1990 to 1991.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 35 years or older.
  2. For GWI cases, served in the 1990-1991 Gulf War as active duty, national guard, or reserves and meet criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.
  3. For controls, must be a veteran in the same age range as those veterans with GWI as defined above.
  4. Ability to understand written and spoken English or availability of a legal representative who can understand written or spoken English. Participants and caregiver/informants must be able to read, write and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate testing.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed or being treated by a physician for any of the following (Steele et al, 2000) and deemed per the discretion of the PI:

    1. Cancer (except for non-melanoma skin cancers)
    2. Chronic infectious disease
    3. Problems resulting from postwar injuries.
    4. Liver disease
    5. Lupus
    6. Multiple sclerosis
    7. Stroke
    8. Serious psychiatric condition (those associated with psychosis and/or for which the respondent had been hospitalized since 1991).
    9. Dementia or any type of Parkinson's disease (PD).
  2. Hospitalized in the last 5 years for alcohol or drug dependence, depression, or post-traumatic stress disorder (PTSD).
  3. Female subject is either pregnant or nursing.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case: GWI

    This group includes participants who served in the Gulf War during 1990 -1991 and have Gulf War Illness based on either the Kansas or CDC symptom criteria.

  • Control

    This group includes participants who served in the Gulf War during 1990 -1991 and have no symptoms of Gulf War Illness based on both the Kansas and CDC symptom criteria.

06

What researchers measure

Primary outcomes

  1. Validate Blood Biomarkers

    To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.

    Time frame: 2022-2024

  2. Identify Blood/Lipid Profiles

    To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI.

    Time frame: 2022-2024

  3. Effect of Dietary, Medical and Biological Factors

    To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans.

    Time frame: 2022-2024

  4. Metabolites Correlating with Cognitive Decline

    To identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI.

    Time frame: 2022-2024

07

Study locations

3 of 3 sites recruiting
  • Palto Alto Veterans Institute for Research
    Palo Alto, California 94304, United States
    Recruiting
    • Raj Brar · ContactRBrar@pavir.org · 650-374-9073
    • Maheen Adamson, Ph.D · Sub investigator
  • The Roskamp Institute
    Sarasota, Florida 34232, United States
    Recruiting
    • Dakota M Helgager, B.S. · Contactdhelgager@roskampclinic.org · 941-256-8019
    • Laila Abdullah, Ph.D · Principal investigator
    • Michael Hoffmann, MD · Sub investigator
  • Boston University
    Boston, Massachusetts 02118, United States
    Recruiting
    • Leah Orlinsky · Contactbbrain@bu.edu · 617-358-2214
    • Kim Sullivan, Ph.D · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2025, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Feb 21, 2023
StartActual
Jun 30, 2022
Primary completionEst.
Dec 1, 2025
CompletionEst.
Mar 1, 2026
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05736146
Lead sponsor
Roskamp Institute Inc.
Collaborators
Boston University, Palo Alto Veterans Institute for Research, United States Department of Defense
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jun 30, 2022
Primary completion
Dec 1, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Jul 24, 2025

Study contacts

Dakota Helgager, B.S
Contact
dhelgager@roskampclinic.org
(941) - 256 - 8019 ext. 3008
Laila Abdullah, Ph.D.
principal investigator · The Roskamp Institute
Michael Hoffmann, MD
principal investigator · The Roskamp Institute
Kim Sullivan, Ph.D
principal investigator · Boston University
Maheen Adamson, Ph.D.
principal investigator · Palo Alto Veterans Institute of Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion